Matinas BioPharma Holdings (MTNB) Return on Sales (2015 - 2023)

Matinas BioPharma Holdings (MTNB) has 9 years of Return on Sales data on file, last reported at 0.22% in Q4 2023.

• Return on Sales for Q4 2023 came in at 0.22%, down 17.0% year-over-year; the trailing twelve-month figure through Dec 2023 was 0.22% (down 14.0% YoY), and the FY2023 annual result was 0.21%, down 13.0% from the prior year.
• Return on Sales eased to 0.22% in Q4 2023 per MTNB's latest filing, from 0.11% in the prior quarter.
• Over five years, Return on Sales peaked at 201.63% in Q4 2021 and troughed at 3.5% in Q2 2021.
• A 5-year average of 12.48% and a median of 0.13% in 2023 frame the typical range for Return on Sales.
• The sharpest annual moves came in 2021 and 2022: Return on Sales soared 20060 bps in 2021, then tumbled 20168 bps in 2022.
• A 5-year view of Return on Sales shows it stood at 2.11% in 2019, then surged by 149 bps to 1.03% in 2020, then jumped by 19424 bps to 201.63% in 2021, then tumbled by 100 bps to 0.05% in 2022, then tumbled by 321 bps to 0.22% in 2023.
• Business Quant data shows MTNB's Return on Sales at 0.22% in Q4 2023, 0.11% in Q3 2023, and 0.09% in Q2 2023.